Adaptive Biotechnologies (ADPT) Share-based Compensation (2018 - 2026)

Adaptive Biotechnologies has disclosed Share-based Compensation across 9 years of filings, most recently posting $11.9 million for Q1 2026.

• Share-based Compensation for Q1 2026 came in at $11.9 million, down 1.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $51.3 million (changed 0.38% YoY), and the FY2025 annual result was $51.5 million, down 3.97% from the prior year.
• Share-based Compensation came in at $11.9 million for Q1 2026 at Adaptive Biotechnologies, down from $12.7 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $17.3 million in Q2 2023 to a low of $11.9 million in Q1 2026.
• The 5-year median for Share-based Compensation is $13.5 million (2024), against an average of $13.8 million.
• Across the five-year window, Share-based Compensation soared 51.59% in 2022 and slipped 25.29% in 2024, its largest moves.
• Adaptive Biotechnologies' Share-based Compensation stood at $14.3 million in 2022, then increased by 8.83% to $15.6 million in 2023, then fell by 17.51% to $12.8 million in 2024, then decreased by 0.87% to $12.7 million in 2025, then fell by 6.23% to $11.9 million in 2026.
• The last three Share-based Compensation figures came in at $11.9 million (Q1 2026), $12.7 million (Q4 2025), and $13.3 million (Q3 2025), per Business Quant data.